Nuvectis Pharma (NVCT) vs REGENXBIO (RGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed REGENXBIO (RGNX) over the past year, gaining 223.1% versus a loss of 33.8%. Nuvectis Pharma is the larger company by market cap ($689.4 million vs $532.7 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVCT | RGNX |
|---|---|---|
| Share price | $21.12 | $8.07 |
| Market cap | $689.44M | $532.73M |
| 1-day change | +4.92% | -0.25% |
| YTD return | +166.62% | -43.82% |
| 1-year return | +223.11% | -33.80% |
| 5-year return | — | -77.50% |
| EPS (TTM) | $-1.31 | $-3.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.28 | $16.19 |
| 52-week low | $5.55 | $5.46 |
| Distance from 52-week high | -27.86% | -50.15% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +67.61% | +192.19% |
| Average volume | 215.43K | 1.53M |
| Shares outstanding | 32.64M | 66.01M |
| Employees | 16 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed RGNX by 256.9 percentage points over the past year.
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees
NVCT vs RGNX FAQ
Which is bigger, Nuvectis Pharma or REGENXBIO?
Nuvectis Pharma (NVCT) is larger, with a market capitalization of $689.44M compared with $532.73M for REGENXBIO (RGNX).
Which stock has performed better over the past year, NVCT or RGNX?
NVCT returned +223.11% over the past 12 months, compared with -33.80% for RGNX (price return, excluding dividends). Past performance does not predict future results.
Are Nuvectis Pharma and REGENXBIO in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Nuvectis Pharma and Biotechnology: Biological Products (No Diagnostic Substances) for REGENXBIO.